Simvastatin after orthotopic heart transplantation. Costs and consequences

PharmacoEconomics

Volumn 15, Issue 3, 1999, Pages 279-289

  Krobot, Karl J ^a   Wenke, Klaus ^b   Reichart, Bruno ^c  

^a MSD Sharp and Dohme GmbH   (Germany)

^b Munich Bogenhausen ^*  (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; PREDNISOLONE; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; ECONOMIC ASPECT; ECONOMIC EVALUATION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, DIETARY; COSTS AND COST ANALYSIS; FEMALE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SIMVASTATIN; SURVIVAL ANALYSIS;

EID: 0033002420     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915030-00007     Document Type: Article

References (43)

1. ISHLT 14th Annual Data Report. Available from: URL: http://www.richmond.infi.net/-ishlt/ishlt_97/cause.html#heart_lung [accessed 1997 Jul 8]
2. Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991; 10: 45-9
3. Sharples LD, Caine N, Mullins P, et al. Risk factor analysis for the major hazards following heart transplantation: rejection, infection, and coronary occlusive disease. Transplantation 1991; 52: 244-52
4. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19 (6): 1315-21
5. Schröder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328 (3): 164-70
6. Hidalgo L, Zambrana JL, Blanco-Molina A, et al. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation. J Heart Lung Transplant 1995; 14 (3): 461-7
7. Barbir M, Hunt B, Kushwaha S, et al. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol 1992; 70: 1596-601
8. Kobashigawa JA, Katznelson S, Laks H, et al. Effects of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 33: 621-7
9. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96 (5): 1398-402
10. Ballantyne C, Bourge RC, Domalik LJ, et al. Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant registry. Am J Cardiol 1996; 78: 532-5
11. Christopherson LK. Organ transplantation and artificial organs. Int J Technol Assess Health Care 1986; 2: 553-62
12. Evans RW. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. In: Terasaki PI, Cecka JM, editors. Los Angeles (CA): UCLA Tissue Typing Laboratory, 1993: 359-91
13. Gold MR, Russell LB, Soegel JE, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996
14. ISHLT 14th Annual Data Report. Available from: URL: http://www.richmond.infi.net/~~ishlt/registry/survival.htm#surv_al [accessed 1996 Nov 21]
15. Rote Liste 1997. Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH. Aulendorf/Württemberg: ECV, 1997
16. GOÄ und BG-GOÄ. Gebührenordnung für Ärzte (GOÄ). 8. Auflage. Dachau: Zauner Druck und Verlags GmbH, 1997
17. Haberman S. Heart transplants: putting a price on life. Health Soc Serv J 1982; 90: 877-9
18. Pennock JL, Oyer PE, Reitz BA, et al. Cardiac transplantation in perspective for the future: survival, complications, rehabilitation & cost. J Thorac Cardiovasc Surg 1982; 83: 168-77
19. ISHLT 14th Annual Data Report. Available from: URL: http://www.richmond.infi.net/~ishlt/ishlt_97/survival.html# overall [accessed 1997 Jul 15]
20. Scheld HH, Deng MC, Hammel D, et al. Kosten/Nutzen-Relation der Herztransplantation. Z Kardiol 1994; 83 Suppl. 6: 139-49
21. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian survival study. N Engl J Med 1987; 316: 1429-35
22. van Hout B, Bonsel G, Habbema D, et al. Heart transplantation in the Netherlands: costs, effects and scenarios. J Health Econ 1993; 12: 73-93
23. Lee E. Statistical methods for survival data analysis. Belmont (CA): Wadsworth Inc., 1980: 162-7
24. 1997 Drug Topics Red Book. Montvale (NJ): Medical Economics Company, Inc., 1997
25. The artificial heart: prototypes, policies, and patients. Washington, D.C.: National Academy Press, 1992: 268-9
26. Sharples LD, Briggs A, Caine N, et al. A model for analyzing the cost of main clinical events after cardiac transplantation. Transplantation 1996; 62 (5): 615-21
27. Ammerman AS, Devellis RF, Keyserling TC, et al. Quality of life is not adversely affected by a dietary intervention to reduce cholesterol [abstract]. Circulation 1993; 87: 19
28. Lawrence WF, Fryback DG, Martin PA. Cholesterol and health status in the Beaver Dam Health Outcomes Study [abstract]. Med Decis Making 1994; 14: 436
29. Zimmermann R, Haverich A. Herztransplantation [editorial]. Fortschr Kardiol 1996; 1: 22
30. Anhang I (zu Artikel I Nr. 3) der Dritten Verordnung zur Änderung der Bundespflegesatzverordnung. Bundesgesetzblatt (BGBI.) I, Nr 68 vom 28. Köln: Bundesanzeiger Verlagsges mbH, 1995: 2006-12
31. Statistisches Bundesamt. Statistisches Jahrbuch für die Bundesrepublik Deutschland. Wiesbaden: Statistisches Bundesamt, 1997
32. United Network for Organ Sharing (UNOS). UNOS OPTN/Scientific Registry data. Richmond (VA): UNOS, 1997
33. Hauboldt RH. Cost implications of human organ transplantations: an update. Brookfield (CT): Milliman and Robertson, Inc., 1993
34. Poirier VL. The economic burden of artificial hearts: progress in artificial organs. Cleveland (OH): ISAO Press, 1986: 96-9
35. Discounting health care: only a matter of timing? Lancet 1992; 340: 148-9
36. Smith PE, Eydelloth RS, Grossman SJ, et al. HMG-CoA-Reductase inhibitor induced myopathy in the rat: cyclosporine interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225-30
37. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202
38. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
39. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Eur Heart J 1996; 17: 1001-7
40. Malik IS, Anderson MH. Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study [abstract]. Heart 1996; 75 Suppl. 1: 77
41. European Transplant Coordinators Organization (ETCO) Statistics. Available from: URL: http://www.kuleuven.ac.be/facdep/medicine/etco [accessed 1997 Jul 8]
42. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301-7
43. Institute of Medicine (IOM). National priorities for the assessment of clinical conditions and medical technologies. Washington, D.C.: National Academy Press, 1990